Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: crimson who wrote (10147)	11/11/1998 7:25:00 PM
From: TokyoMex	Respond to of 119973

ALLP News .. Not bad at all ,, we got our phase III load of cash ,, earnings sucks,,but then they are bio-med,, Wednesday November 11, 6:57 pm Eastern Time Company Press Release SOURCE: Alliance Pharmaceutical Corp. Alliance Pharmaceutical Corp. Announces First Quarter Financial Results SAN DIEGO, Nov. 11 /PRNewswire/ -- Alliance Pharmaceutical Corp. (Nasdaq: ALLP - news) today reported a net loss of $10.7 million, or $0.33 per share, for its first fiscal quarter ended September 30, 1998, compared to a net loss of $6.4 million, or $0.20 per share, for the quarter ended September 30, 1997. The Company reported revenues of $5.1 million, primarily research revenue under its license agreement with Schering AG, Germany for Imagent®. Revenues for the quarter ended September 30, 1997 were $6.5 million, which included a license fee of $4 million from Schering AG, Germany. Operating expenses for the quarter totaled $15.7 million, compared to $13.9 million for the 1997 quarter. The increase in operating expenses is primarily attributable to increased staffing and related costs as the Company continues the Phase 3 Imagent trials and prepares for Phase 3 trials for Oxygent™ and LiquiVent®. As required by the Securities and Exchange Commission, the Company's financial results include a one-time, non-cash imputed dividend of $483,000 from the sale of the its convertible Series E-1 Preferred Stock, which raised approximately $5.6 million in August 1998. The Company reported cash and short-term investments of $43.3 million at September 30, 1998.